Summary
Bristol-Myers Squibb Misses
Bristol-Myers Squibb (BMY) reported Quarter December 2025 earnings of $1.26 per share on revenue of $12.5 billion. The consensus earnings estimate was $1.15 per share on revenue of $12.3 billion. The Earnings Whisper number was $1.42 per share. Revenue grew 1.3% on a year-over-year basis.
The company said it expects 2026 earnings of $6.05 to $6.35 per share on revenue of $46.0 billion to $47.0 billion. The current consensus earnings estimate is $6.08 per share on revenue of $44.1 billion for the year ending December 31, 2026.
Bristol-Myers Squibb Co is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products.
Results
Reported Earnings
$1.26
Earnings Whisper
$1.42
Consensus Estimate
$1.15
Reported Revenue
$12.50 Bil
Revenue Estimate
$12.26 Bil
Growth
Earnings Growth
Revenue Growth
Earnings Release
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results.
Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed fourth quarter and full-year 2025 earnings press release and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here. Company executives will review financial results with the investment community during the call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
corporatefinancial-news
View source version on businesswire.com: https://www.businesswire.com/news/home/20260205453283/en/
For more information, contact:
Media Relations: media@bms.com
Investor Relations: investor.relations@bms.com
Source: Bristol Myers Squibb
